Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.64 |
| ▸ | HTR3A | P46098 | 3/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.43 |
| ▸ | WNT1 | P04628 | 4/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15199683 | 0.91 | CHRNA7 (0.62) | CHRNA7HTR3ADYRK1AWNT1HTR3E | |
| SCHEMBL2791345 | 0.86 | CHRNA7 (0.71) | CHRNA7HTR3ADYRK1AWNT1HTR3E | |
| SCHEMBL2790338 | 0.86 | CHRNA7 (0.71) | CHRNA7HTR3ADYRK1AWNT1HTR3E | |
| SCHEMBL12059780 | 0.86 | CHRNA7 (0.63) | CHRNA7HTR3ADYRK1AWNT1HTR3E | |
| SCHEMBL1967265 | 0.86 | CHRNA7 (0.65) | CHRNA7HTR3ADYRK1AWNT1 | |
| SCHEMBL1965176 | 0.86 | CHRNA7 (0.67) | CHRNA7HTR3ADYRK1AWNT1HTR3E | |
| SCHEMBL1965165 | 0.85 | CHRNA7 (0.62) | CHRNA7HTR3ADYRK1AWNT1HTR3E | |
| SCHEMBL1965388 | 0.85 | CHRNA7 (0.62) | CHRNA7HTR3ADYRK1AWNT1HTR3E | |
| SCHEMBL1966902 | 0.85 | CHRNA7 (0.69) | CHRNA7HTR3ADYRK1AWNT1 | |
| SCHEMBL1963831 | 0.84 | CHRNA7 (0.60) | CHRNA7HTR3ADYRK1AWNT1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486937-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-8263619-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 367/4885JAK2 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.